Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229–263 (2024).

PubMed  Google Scholar 

Pabla, B. S., Shah, S. C., Corral, J. E. & Morgan, D. R. Increased incidence and mortality of gastric cancer in immigrant populations from high to low regions of incidence: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 18, 347–359.e5 (2020).

Article  PubMed  Google Scholar 

Petrillo, A. & Smyth, E. C. 27 years of stomach cancer: painting a global picture. Lancet Gastroenterol. Hepatol. 5, 5–6 (2020).

Article  PubMed  Google Scholar 

Rumgay, H. et al. International trends in esophageal squamous cell carcinoma and adenocarcinoma incidence. Am. J. Gastroenterol. 116, 1072–1076 (2021).

Article  PubMed  Google Scholar 

Ben-Aharon, I. et al. Early-onset cancer in the gastrointestinal tract is on the rise-evidence and implications. Cancer Discov. 13, 538–551 (2023).

Article  CAS  PubMed  Google Scholar 

Lumish, M. A. et al. Clinical and molecular characteristics of early-onset vs average-onset esophagogastric cancer. J. Natl Cancer Inst. 116, 299–308 (2024).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qu, X. et al. The clinicopathological characteristics of early-onset gastric cancer and its evolutionary trends: a retrospective study. Am. J. Cancer Res. 12, 2757–2769 (2022).

CAS  PubMed  PubMed Central  Google Scholar 

Pan, K. F. et al. Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial. Nat. Med. 30, 3250–3260 (2024).

Article  CAS  PubMed  Google Scholar 

National Cancer Institute. The Surveillance, Epidemiology, and End Results (SEER) Program. Cancer Statistics Review. NCI https://seer.cancer.gov/statfacts/html/stomach.html and https://seer.cancer.gov/statfacts/html/esoph.html (2026).

National Oesophago-Gastric Cancer Audit. State of the Nation Report 2025. NOGCA https://www.natcan.org.uk/wp-content/uploads/2025/09/NOGCA-State-of-the-Nation-Report-September-2025-Version-2.pdf (2025).

Cancer Statistics In Japan 2025. https://ganjoho.jp/public/qa_links/report/statistics/pdf/cancer_statistics_2025_fig_E.pdf (2025).

Chen, Y. et al. The current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China: a comprehensive nationwide cohort analysis. J. Hematol. Oncol. 18, 42 (2025).

Article  PubMed  PubMed Central  Google Scholar 

Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359, 1727–1733 (2002).

Article  Google Scholar 

Allum, W. H., Stenning, S. P., Bancewicz, J., Clark, P. I. & Langley, R. E. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J. Clin. Oncol. 27, 5062–5067 (2009).

Article  PubMed  Google Scholar 

Cunningham, D. et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 355, 11–20 (2006).

Article  CAS  PubMed  Google Scholar 

Alderson, D. et al. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. Lancet Oncol. 18, 1249–1260 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ychou, M. et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J. Clin. Oncol. 29, 1715–1721 (2011).

Article  CAS  PubMed  Google Scholar 

Al-Batran, S. E. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 393, 1948–1957 (2019).

Article  PubMed  Google Scholar 

Obermannová, R. et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 35, 673–690 (2024).

Google Scholar 

Sakuramoto, S. et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N. Engl. J. Med. 357, 1810–1820 (2007).

Article  CAS  PubMed  Google Scholar 

Noh, S. H. et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 15, 1389–1396 (2014).

Article  CAS  PubMed  Google Scholar 

Park, S. H. et al. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J. Clin. Oncol. 33, 3130–3136 (2015).

Article  CAS  PubMed  Google Scholar 

Kakeji, Y. et al. Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07. Gastric Cancer 25, 188–196 (2022).

Article  CAS  PubMed  Google Scholar 

Park, S. H. et al. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial. Ann. Oncol. 32, 368–374 (2021).

Article  CAS  PubMed  Google Scholar 

Kang, Y. K. et al. Neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 for resectable advanced gastric cancer: updated overall survival outcomes from phase III PRODIGY. J. Clin. Oncol. 42, 2961–2965 (2024).

Article  PubMed  Google Scholar 

Zhang, X. et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial. Lancet Oncol. 26, 312–319 (2025).

Article  PubMed  Google Scholar 

Macdonald, J. S. et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. 345, 725–730 (2001).

Article  CAS  PubMed  Google Scholar 

Smalley, S. R. et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J. Clin. Oncol. 30, 2327–2333 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cats, A. et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 19, 616–628 (2018).

Article  CAS  PubMed  Google Scholar 

de Steur, W. O. et al. Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial. Ann. Oncol. 32, 360–367 (2021).

Article  PubMed  Google Scholar 

van Hagen, P. et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N. Engl. J. Med. 366, 2074–2084 (2012).

Article  PubMed  Google Scholar 

Shapiro, J. et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 16, 1090–1098 (2015).

Article  PubMed  Google Scholar 

Hoeppner, J. et al. Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer. N. Engl. J. Med. 392, 323–335 (2025).

Article  PubMed  Google Scholar 

Hoeppner, J. et al. Recurrence patterns of esophageal adenocarcinoma in the phase III ESOPEC trial comparing perioperative chemotherapy with preoperative chemoradiotherapy. J. Clin. Oncol. 43, 3451–3456 (2025).

Article  PubMed  Google Scholar 

Leong, T. et al. Preoperative chemoradiotherapy for resectable gastric cancer. N. Engl. J. Med. 391, 1810–1821 (2024).

Article  CAS